BioLife Solutions - Public Comps and Valuation Multiples

BioLife Solutions Overview

About BioLife Solutions

BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

Founded

1987

HQ

Employees

159

Website

biolifesolutions.com

Sectors

Medical Supplies
Laboratory Services

Financials

LTM Revenue $96.9M

LTM EBITDA $22.0M

EV

$1.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

BioLife Solutions Financials

As of September 2025, BioLife Solutions reported last 12-month revenue of $96.9M and EBITDA of $22.0M.

In the same period, BioLife Solutions generated $60.8M in LTM gross profit and -$15.6M in net income.

See BioLife Solutions valuation multiples based on analyst estimates

BioLife Solutions P&L

In the most recent fiscal year, BioLife Solutions reported revenue of $82.3M and EBITDA of $1.5M.

BioLife Solutions expects next 12-month revenue of XXX and NTM EBITDA of XXX

See BioLife Solutions valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$96.9M	XXX	$82.3M	XXX	XXX	XXX
Gross Profit	$60.8M	XXX	$53.7M	XXX	XXX	XXX
Gross Margin	63%	XXX	65%	XXX	XXX	XXX
EBITDA	$22.0M	XXX	$1.5M	XXX	XXX	XXX
EBITDA Margin	23%	XXX	2%	XXX	XXX	XXX
EBIT	-$17.2M	XXX	-$7.1M	XXX	XXX	XXX
EBIT Margin	-18%	XXX	-9%	XXX	XXX	XXX
Net Profit	-$15.6M	XXX	-$20.2M	XXX	XXX	XXX
Net Margin	-16%	XXX	-25%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for BioLife Solutions including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $96.9M. EBITDA for the last twelve months was $22.0M. In the most recent fiscal year, BioLife Solutions achieved $82.3M in revenue and $1.5M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$96.9M	Analyst estimates available to subscribers	$82.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$60.8M	Analyst estimates available to subscribers	$53.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	62.7% gross margin	Analyst estimates available to subscribers	65.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$22.0M	Analyst estimates available to subscribers	$1.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	22.7% EBITDA margin	Analyst estimates available to subscribers	1.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$17.2M	Analyst estimates available to subscribers	-$7.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-17.7% EBIT margin	Analyst estimates available to subscribers	-8.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$15.6M	Analyst estimates available to subscribers	-$20.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-16.1% net profit margin	Analyst estimates available to subscribers	-24.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for BioLife Solutions

This financial data table provides comprehensive performance metrics for BioLife Solutions, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

BioLife Solutions generated $96.9M in revenue over the last twelve months.
The company achieved $22.0M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $60.8M.
Net income over the last twelve months reached -$15.6M.

Fiscal Year Performance

In the most recent fiscal year, BioLife Solutions reported $82.3M in total revenue.
Fiscal year EBITDA was $1.5M.
The company maintained a gross profit margin of 65.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 1.9%.
Net profit margin reached -24.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for BioLife Solutions. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

BioLife Solutions Stock Performance

BioLife Solutions has current market cap of $1.2B, and EV of $1.2B.

Market Cap Evolution

BioLife Solutions Stock Data

As of October 3, 2025, BioLife Solutions's stock price is $26.

See BioLife Solutions trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.2B	$1.2B	XXX	XXX	XXX	XXX	$-0.33

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

BioLife Solutions Valuation Multiples

BioLife Solutions's trades at 14.4x EV/Revenue multiple, and 772.4x EV/EBITDA.

See valuation multiples for BioLife Solutions and 15K+ public comps

BioLife Solutions Financial Valuation Multiples

As of October 3, 2025, BioLife Solutions has market cap of $1.2B and EV of $1.2B.

Equity research analysts estimate BioLife Solutions's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

BioLife Solutions has a P/E ratio of -79.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.2B	XXX	$1.2B	XXX	XXX	XXX
EV (current)	$1.2B	XXX	$1.2B	XXX	XXX	XXX
EV/Revenue	12.2x	XXX	14.4x	XXX	XXX	XXX
EV/EBITDA	53.8x	XXX	772.4x	XXX	XXX	XXX
EV/EBIT	-68.8x	XXX	-166.0x	XXX	XXX	XXX
EV/Gross Profit	19.5x	XXX	n/a	XXX	XXX	XXX
P/E	-79.5x	XXX	-61.5x	XXX	XXX	XXX
EV/FCF	86.2x	XXX	241.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BioLife Solutions Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

BioLife Solutions Margins & Growth Rates

BioLife Solutions's last 12 month revenue growth is 18%

BioLife Solutions's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.

BioLife Solutions's rule of 40 is -13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

BioLife Solutions's rule of X is 68% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for BioLife Solutions and other 15K+ public comps

BioLife Solutions Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	18%	XXX	20%	XXX	XXX	XXX
EBITDA Margin	23%	XXX	2%	XXX	XXX	XXX
EBITDA Growth	40%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-13%	XXX	20%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	68%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	12%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	10%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	74%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial